uTRACE®
uTRACE® is Curasight’s uPAR-targeted imaging and diagnostic platform.
Individual imaging agents within the platform are defined by their specific ligand, chelator, radionuclide and intended use. The accumulated uTRACE® evidence supports the broader uPAR strategy, but individual imaging agents are not necessarily identical to, or paired one-to-one with, individual uTREAT® therapeutic product candidates.
The most advanced diagnostic program evaluates uTRACE® for non-invasive characterization of prostate cancer aggressiveness in patients in active surveillance. Earlier prospective clinical work demonstrated a significant relationship between uPAR PET uptake and Gleason grade. The prostate cancer indication is licensed to Curium, with development responsibilities allocated between the parties under their agreement.
uTRACE® and related nine uPAR PET clinical trials have imaged more than 500 patients across eight cancer settings.
Broader uTRACE® clinical evidence
Beyond prostate cancer, studies have investigated uPAR PET in glioma, head and neck cancer, neuroendocrine neoplasms, breast cancer, non-small cell lung cancer and bladder cancer, among other settings.
These studies are important to Curasight for two reasons: they evaluate uTRACE® as an imaging and prognostic tool of value in patient management, and they provide human data on where uPAR can be visualized as Curasight prioritizes future therapeutic indications.
Explore the pipeline
Science
See the target. Measure where the radiation goes
Clinical evidence
A clinical program spanning imaging, prognosis, diagnosis and the first human delivery and dosimetry study supporting therapeutic development.
Pipeline
From human target validation to therapeutic development